Ozempic Users See 15% Fewer Bone Fractures in Study

People taking Ozempic for type 2 diabetes just got some unexpected good news about their bone health.

A large study analyzing nearly 60,000 patients found that those using semaglutide (sold as Ozempic, Wegovy, and Rybelsus) experienced 15% fewer bone fractures than people taking other weight-loss medications. This came as a welcome surprise to researchers, who had worried that rapid weight loss might actually weaken bones.

The findings were presented at the Endocrine Society's annual meeting in Chicago. Researchers led by Dr. Jairo Noreña examined health records from 161 million patients treated at U.S. hospitals between 2016 and 2023.

They compared 26,324 people taking semaglutide with 33,555 people using other common weight-loss drugs. All participants had type 2 diabetes and no history of fractures or osteoporosis medications.

The semaglutide group recorded 794 fractures total, while the comparison group experienced 1,045 fractures. This happened even though semaglutide users lost more weight, which traditionally raises concerns about bone thinning.

Semaglutide belongs to a class of drugs called GLP-1 receptor agonists. Previous research had raised red flags that rapid weight loss from these medications might compromise bone density and increase fracture risk.

This real-world data tells a different story. Patients got the weight-loss benefits they wanted while potentially gaining extra protection for their bones.

The Bright Side

Bone fractures aren't just painful. They're expensive, can seriously impact quality of life, and become increasingly dangerous as people age.

For the millions of Americans managing type 2 diabetes and obesity, this research offers reassurance. The medication that's helping them lose weight may simultaneously be protecting their skeletal health.

Dr. Noreña emphasized that bone fractures carry serious consequences beyond the immediate pain. Recovery can be lengthy, medical costs add up quickly, and older adults face particular risks from falls and breaks.

The researchers hope their findings encourage healthcare providers to monitor bone health more closely in weight-loss programs. Understanding how different medications affect the whole body helps doctors and patients make better informed choices.

While the results are promising, the team notes that additional prospective studies are needed to confirm the protective effect. This study looked backward at existing records rather than following patients forward over time.

For now, people taking semaglutide can feel encouraged that their treatment appears to support multiple aspects of their health at once.